Quantcast

Latest DUSA Pharmaceuticals Stories

2011-05-11 15:05:00

NASHVILLE, Tenn., May 11, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the 2011 UBS Global Specialty Pharmaceuticals Conference in London on Wednesday, May 25, 2011, at 12:30 p.m. The presentation will be simultaneously webcast and can be accessed by visiting the Investor Relations section of Cumberland...

2010-11-11 07:30:00

WILMINGTON, Mass., Nov. 11, 2010 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (Nasdaq GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the 4th Annual Maxim Group Growth Conference on Thursday, November 18, 2010 at 8:30...

2010-11-02 05:30:00

WILMINGTON, Mass., Nov. 2, 2010 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (Nasdaq: DUSA) announces that its third quarter corporate highlights and financial results press release will be issued on Friday, November 5th at 6:30 a.m. to be followed by a conference call at 8:30 a.m. Friday, November 5th - 8:30 a.m. E.D.T. If calling from North America use the following toll-free number: 800-647-4314...

2010-10-26 14:33:00

WILMINGTON, Mass., Oct. 26 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology announced today that it has been named to Deloitte's 2010 Technology Fast 500 list. For the third consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications, life sciences, and clean technology companies in North America. Rankings are based on percentage of...

2010-09-07 07:30:00

WILMINGTON, Mass., Sept. 7 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 12th Annual Healthcare Conference on Monday, September 13, 2010 at 10:50...

2010-08-06 11:01:00

WILMINGTON, Mass., Aug. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(® )(Nasdaq: DUSA) reported today that on the afternoon of August 5, 2010 the U.S. Food and Drug Administration (FDA) notified DUSA that it has not granted Orphan Drug Designation for the use of Levulan(®) (aminolevulinic acid HCl) Photodynamic Therapy (PDT) for the prevention of cutaneous squamous cell carcinomas (SCCs) in patients who have a proven history of multiple...

2010-07-29 05:30:00

WILMINGTON, Mass., July 29 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (Nasdaq: DUSA) announces that its second quarter corporate highlights and financial results press release will be issued on Tuesday, August 3rd at 6:30 a.m. to be followed by a conference call at 8:30 a.m. Tuesday, August 3rd - 8:30 a.m. E.D.T. If calling from North America use the following toll-free number: 800-647-4314...

2010-06-24 05:30:00

All Claims Upheld at Conclusion of Successful Reexamination Process WILMINGTON, Mass., June 24 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(®) (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan(®) Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office (USPTO) has completed its re-examination of US Patent No. 5,079,262, "Method of detection and treatment of malignant and...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related